Roche Reports 43.1% Proteinuria Reduction in IgAN Phase III

Interim phase III data showed investigational sefaxersen reduced proteinuria by 43.1% versus placebo at 37 weeks in adults with IgA nephropathy. Safety was consistent with prior studies; the blinded study continues to assess eGFR change at week 105.